TLR9 and prostate carcinoma: CPG-1668 had no effect on the growth of human prostate cancer (LnCAP) and nonmalignant cell lines, suggesting this observation was not specific to the RM1 cell line, although it should be noted that CPG-1668 has a higher specificity for mouse TLR9 [75].